Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC1R | Q01726 | 5/20 | 0.47 |
| ▸ | MC4R | P32245 | 12/20 | 0.43 |
| ▸ | MC5R | P33032 | 4/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946750 | 0.87 | SIGMAR1 (0.45) | KCNH2SIGMAR1 | |
| SCHEMBL1920459 | 0.85 | MC4R (0.45) | MC1RMC4RMC5RKCNH2MC3R | |
| SCHEMBL1970760 | 0.84 | SLC6A4 (0.47) | SLC6A4 | |
| SCHEMBL1920759 | 0.79 | MC4R (0.45) | MC1RMC4RMC5RKCNH2MC3R | |
| SCHEMBL3160669 | 0.76 | MC4R (0.51) | MC1RMC4RMC5RPRCPSIGMAR1 | |
| SCHEMBL29327329 | 0.76 | MC4R (0.51) | MC1RMC4RMC5RPRCPSIGMAR1 | |
| SCHEMBL3160673 | 0.76 | MC4R (0.51) | MC1RMC4RMC5RPRCPSIGMAR1 | |
| SCHEMBL1920885 | 0.76 | MC4R (0.48) | MC1RMC4RMC5RKCNH2MC3R | |
| SCHEMBL1920256 | 0.76 | MC4R (0.48) | MC1RMC4RMC5RKCNH2MC3R | |
| SCHEMBL1920336 | 0.76 | SLC6A4 (0.42) | SLC6A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716135-B1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LTD (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MC4R, MC5R, GPR4 | MC1R 6/4885MC4R 1/4885MC5R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.